- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| BIO-WORKS TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| 15.10. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies AB announces outcome from exercise of warrants of series TO 2. Exercise period 8 of 11 | 1 | Cision News | ||
| 01.10. | BIO-WORKS TECHNOLOGIES AB: Today is the first day of the eighth exercise period for Bio-Works Technologies AB's warrants of series TO 2 | 1 | Cision News | ||
| 01.10. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies AB - Business Update third quarter 2026 | 1 | Cision News | ||
| 27.08. | BIO-WORKS TECHNOLOGIES AB: Bio-Works brings forward the publication of its interim report for the third quarter of 2026 | 1 | Cision News | ||
| 25.08. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Secures New US Customer in the Development of Next-Generation Medicine | 2 | Cision News | ||
| 21.08. | BIO-WORKS TECHNOLOGIES AB: Bio-Works reports second quarter 2026 | 1 | Cision News | ||
| 18.08. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies AB appoints Eva Lindskog as new CEO | 1 | Cision News | ||
| 17.07. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Receives Order for 22,6 MSEK from Returning Customer | 2 | Cision News | ||
| 15.07. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies AB announces outcome from exercise of warrants of series TO 2. Exercise period 7 of 11 | 1 | Cision News | ||
| 06.07. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Receives Order for 8,9 MSEK from Returning Customer | 1 | Cision News | ||
| 01.07. | BIO-WORKS TECHNOLOGIES AB: Today is the first day of the seventh exercise period for Bio-Works Technologies AB's warrants of series TO 2 | 1 | Cision News | ||
| 01.07. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies AB - Business Update second quarter 2026 | 1 | Cision News | ||
| 04.06. | BIO-WORKS TECHNOLOGIES AB: Resolutions passed at Bio-Works Technologies' annual general meeting 2026 | 1 | Cision News | ||
| 13.05. | BIO-WORKS TECHNOLOGIES AB: Bio-Works reports first quarter 2026 | 2 | Cision News | ||
| 29.04. | BIO-WORKS TECHNOLOGIES AB: Bio-Works receives order for WorkBeads 40S from contract manufacturer in Europe | 1 | Cision News |
15 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| HELIX BIOPHARMA | 0,460 | +4,55 % | Early Warning Press Release Regarding The Disposition Of Common Shares Of Helix Biopharma Corp. By Jerzy Wilczewski | ||
| DAMORA THERAPEUTICS | 21,140 | +0,24 % | Damora Therapeutics, Inc.: Damora Announces Redomestication from Delaware to Cayman Islands | BOSTON, July 17, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (Damora or the Company) (NASDAQ: DMRA), a biotechnology company working to fundamentally redefine care for patients with blood disorders... ► Artikel lesen | |
| QIAGEN | 45,050 | +0,26 % | Finanzinvestor EQT will Qiagen für über 9 Milliarden Euro kaufen - Agentur | DJ Finanzinvestor EQT will Qiagen für über 9 Milliarden Euro kaufen - Agentur
DOW JONES--Der Finanzinvestor EQT will einem Agenturbericht zufolge den Diagnostikspezialisten Qiagen übernehmen. Wie... ► Artikel lesen | |
| TANGO THERAPEUTICS | 23,360 | +0,09 % | Wedbush raises Tango Therapeutics stock price target on trial data | ||
| COGENT BIOSCIENCES | 31,210 | 0,00 % | If You Invested $1000 In Cogent Biosciences Stock 5 Years Ago, You Would Have This Much Today | ||
| SUMMIT THERAPEUTICS | 15,470 | 0,00 % | Akeso, Inc.: Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer | Becomes the 7th International Registrational Clinical Trial for Ivonescimab
Clinical Trial Site Activations in the United States Expected to Begin Q4 2026
HONG... ► Artikel lesen | |
| MODERNA | 178,42 | -0,19 % | Apple ein sicherer Hafen: Moderna: Kurseinbruch | Bloom: Rücksetzer ausnutzen? | Telekom: Starlink-Panik | Die Deutsche Telekom steht mal wieder unter Druck. SpaceX verhandelt wohl über den Zugang zu 80.000 Mobilfunkmasten in den USA. Damit dürfte wohl für T-Mobile, AT&T und Verizon die Konkurrenz deutlich... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 76,73 | 0,00 % | AstraZeneca, Cardiol Therapeutics, Kiniksa - Neue Hoffnung für Herzpatienten | Herz-Kreislauf-Erkrankungen gehören weltweit zu den größten medizinischen Herausforderungen. Während etablierte Pharmakonzerne Milliarden in neue Wirkstoffe und Künstliche Intelligenz investieren, entwickeln... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 27,200 | 0,00 % | Biotech Stocks At 52-Week Highs - Amylyx Pharmaceuticals +63% With Phase 3 Data, Vogenx +25%, Orchestra BioMed +19%, AtriCure, Charles River Laboratories | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on August 18, 2026, primarily driven by positive quarterly reports.Amylyx Pharmaceuticals Inc. (AMLX)Amylyx Pharmaceuticals... ► Artikel lesen | |
| LYCIA THERAPEUTICS | 29,560 | -1,47 % | Lycia Therapeutics Prices Upsized $317.5 Mln IPO At $18/Share | WASHINGTON (dpa-AFX) - Lycia Therapeutics Inc. (LYCA) a clinical-stage biotechnology company developing treatments for autoimmune, inflammatory, and allergic diseases, said Thursday it priced... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 41,520 | 0,00 % | H.C. Wainwright hebt Kursziel für Enliven Therapeutics auf 73 $ an | ||
| PRAXIS PRECISION MEDICINES | 252,88 | -0,03 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| ARRIVENT BIOPHARMA | 21,010 | +0,05 % | ArriVent to present phase 1 data for ARR-217 at ESMO | ||
| BOLT BIOTHERAPEUTICS | 6,250 | -0,32 % | Bolt Biotherapeutics, Inc. - 8-K, Current Report | ||
| TRAVERE THERAPEUTICS | 50,05 | 0,00 % | Biotech Stocks At 52-Week Highs - Bioventus, Travere Therapeutics, Odyssey Therapeutics, Charles River Laboratories Climb With Q2 Results, Aclaris Therapeutics | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on August 5, 2026, primarily driven by positive quarterly reports.Bioventus Inc. (BVS)Bioventus is a medical device... ► Artikel lesen |
Das Unternehmen BIO-WORKS TECHNOLOGIES AB kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,007 (-2,64 %) liegt der Kurs bei 0,258 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIO-WORKS TECHNOLOGIES AB finden Sie auf Wallstreet Online.